AstraZeneca PLC (AZN.L)

12,026.00 +674.00 (+5.94%) 收市：05:15PM BST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 89,900

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Executive Director	4.57M	無	1959
Dr. Aradhana Sarin M.D.	CFO & Executive Director	2.52M	無	1974
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	無	無	1970
Mr. Andrew P. Barnett	Head of Investor Relations	無	無	無
Mr. Jeffrey Pott	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	無	無	無
Gonzalo Vina	Head of Global Media Relations	無	無	無
Dr. Menelas Nicolas Pangalos Ph.D.	Executive Vice-President	無	無	1967
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit	無	無	無
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology Research & Development	無	無	1966
Mr. Leon Wang	Executive VP of International & China President	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 GBp。

描述

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

公司管治

截至 2024年4月1日 止，AstraZeneca PLC 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：5；董事會：3；股東權利：9；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。